product summary
Loading...
company name :
R&D Systems
product type :
antibody
product name :
HBsAg Antibody (Hs33) [DyLight 488]
catalog :
NB100-73138G
quantity :
0.2 ml
price :
459 USD
clonality :
monoclonal
host :
mouse
conjugate :
DyLight488
clone name :
Hs33
reactivity :
Hepatitis B virus
application :
ELISA
more info or order :
product information
brand :
Novus
master code :
NB100-73138G
SKU :
NB100-73138G
product name :
HBsAg Antibody (Hs33) [DyLight 488]
sizes available :
0.2 ml
description :
The HBsAg Antibody (Hs33) [DyLight 488] from NB100-73138G is a 6.7e-05 antibody to . This antibody reacts with virus.
target :
HBsAg
category :
Primary Antibodies
buffer :
50mM Sodium Borate
clonality :
Monoclonal
clone :
Hs33
conjugate :
DyLight 488
all_available conjugate :
Janelia Fluor 646;Janelia Fluor 669;DyLight 488
dilution :
Sandwich ELISA
host :
Mouse
immunogen :
Hybridoma clone has been derived from hybridization of Sp2/0 myeloma cells with spleen cells of Balb/c mice immunized with recombinant HBsAg of ayw subtype.
isotype :
IgG2a
purity :
Protein G purified
species :
Virus
specificity :
This reacts with the following HBsAg subtypes: ayw1, ayw2, ayw3, ayw4, ayr, adw2, adw4, adrq+, adrq-, ayw3 (Fer).
gene symbol :
S
applications :
Sandwich ELISA
USD :
459 USD
alt names :
HBsAg, HBV major surface antigen, HBV surface antigen, Hepatitis B Virus major surface antigen, Hepatitis B Virus Surface Antigen, Major surface antigen, protein S
storage :
Store at 4C in the dark.
more info or order :
company information

R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.
related products
browse more products
questions and comments
